Loading clinical trials...
Loading clinical trials...
This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP)...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Amgen
NCT06721013 · Immune Thrombocytopenia (ITP)
NCT05070845 · Primary Immune Thrombocytopenia
NCT06533098 · Thrombocytopenia, Neonatal Alloimmune
NCT07039422 · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
NCT07007962 · Immune Thrombocytopenia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions